New delivery strategies for the old pentavalent antimonial drugs

被引:68
作者
Frezard, Frederic [1 ]
Demicheli, Cynthia [2 ]
机构
[1] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Fisiol & Biofis, BR-31270901 Belo Horizonte, MG, Brazil
[2] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Quim, BR-31270901 Belo Horizonte, MG, Brazil
关键词
antimony; cyclodextrin; dogs; immunochemotherapy; leishmaniasis; liposomes; meglumine antimoniate; microparticle; pentavalent antimonials; stibogluconate; LIPOSOMAL AMPHOTERICIN-B; EXPERIMENTAL VISCERAL LEISHMANIASIS; STEARYLAMINE-BEARING LIPOSOMES; MEGLUMINE ANTIMONIATE; SODIUM STIBOGLUCONATE; CUTANEOUS LEISHMANIASIS; BETA-CYCLODEXTRIN; BONE-MARROW; BALB/C MICE; RETICULOENDOTHELIAL SYSTEM;
D O I
10.1517/17425247.2010.529897
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Importance of the field: Pentavalent antimonials are the first-line drugs for treatment of the major tropical disease leishmaniasis. However, their use is limited by the need for daily parenteral administration, their severe side effects and treatment failures. As leishmaniasis belongs to the group of neglected diseases, the improvement of old drugs through new delivery approaches has more support than the development of new chemical entities. Areas covered in this review: The review covers, from 1977 to the present, the progress achieved towards pharmaceutically acceptable liposome-based formulations of antimonials, identification of specific ligands for improved targeting of infected macrophages and new approaches for oral and topical delivery of antimonial drugs. What the reader will gain: Insights into the most promising delivery strategies to improve antimonial therapy and the chemical basis and future directions for achieving innovative orally and topically effective formulations. Take home message: The development of drug delivery strategies for the old pentavalent antimonials is a still growing and promising field, with expected innovations in the near future from improved knowledge of antimony chemistry.
引用
收藏
页码:1343 / 1358
页数:16
相关论文
共 98 条
[1]   SYNERGISTIC EFFECT OF GLUCANTIME AND A LIPOSOME-ENCAPSULATED MURAMYL DIPEPTIDE ANALOG IN THERAPY OF EXPERIMENTAL VISCERAL LEISHMANIASIS [J].
ADINOLFI, LE ;
BONVENTRE, PF ;
VANDERPAS, M ;
EPPSTEIN, DA .
INFECTION AND IMMUNITY, 1985, 48 (02) :409-416
[2]  
Adler-Moore Jill, 2003, Curr Opin Investig Drugs, V4, P179
[3]   Tuftsin-bearing liposomes in treatment of macrophage-based infections [J].
Agrawal, AK ;
Gupta, CM .
ADVANCED DRUG DELIVERY REVIEWS, 2000, 41 (02) :135-146
[4]   Targeting to macrophages:: role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages [J].
Ahsan, FL ;
Rivas, IP ;
Khan, MA ;
Suárez, AIT .
JOURNAL OF CONTROLLED RELEASE, 2002, 79 (1-3) :29-40
[5]   CANINE LEISHMANIASIS - CLINICAL, PARASITOLOGICAL AND ENTOMOLOGICAL FOLLOW-UP AFTER CHEMOTHERAPY [J].
ALVAR, J ;
MOLINA, R ;
SANANDRES, M ;
TESOURO, M ;
NIETO, J ;
VITUTIA, M ;
GONZALEZ, F ;
SANANDRES, MD ;
BOGGIO, J ;
RODRIGUEZ, F ;
SAINZ, A ;
ESCACENA, C .
ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY, 1994, 88 (04) :371-378
[6]  
ALVING C R, 1986, Parasitology Today, V2, P101, DOI 10.1016/0169-4758(86)90039-6
[7]   THERAPY OF LEISHMANIASIS - SUPERIOR EFFICACIES OF LIPOSOME-ENCAPSULATED DRUGS [J].
ALVING, CR ;
STECK, EA ;
CHAPMAN, WL ;
WAITS, VB ;
HENDRICKS, LD ;
SWARTZ, GM ;
HANSON, WL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1978, 75 (06) :2959-2963
[8]   LIPOSOMES IN LEISHMANIASIS - EFFECTS OF PARASITE VIRULENCE ON TREATMENT OF EXPERIMENTAL LEISHMANIASIS IN HAMSTERS [J].
ALVING, CR ;
SWARTZ, GM ;
HENDRICKS, LD ;
CHAPMAN, WL ;
WAITS, VB ;
HANSON, WL .
ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY, 1984, 78 (03) :279-286
[9]   DELIVERY OF LIPOSOME-ENCAPSULATED DRUGS TO MACROPHAGES [J].
ALVING, CR .
PHARMACOLOGY & THERAPEUTICS, 1983, 22 (03) :407-424
[10]  
ALVING CR, 1984, LIPOSOME TECHNOLOGY, V2, P55